POSTGRADUATE LEUKEMIA CONFERENCE


LEUKEMIA 2018

ROME (ITALY), MAY 24-25, 2018

CME CREDITS 9.8

Scientific Coordinator
Angelo Michele Carella

Scientific Board
Sergio Amadori, Emanuele Angelucci, Robin Foà,
Giuseppe Saglio, Alessandro M. Vannucchi



ACC MED
ACCADEMIA NAZIONALE DI MEDICINA

SECTION OF HEMATOLOGY

With the patronage of

Società Italiana di Ematologia - SIE

AIL
ASSOCIAZIONE ITALIANA CONTRO LE LEUCEMIE-LINFOMI E MIELOMA
ONLUS

fondazione GIMEMA onlus
per la promozione e lo sviluppo della ricerca scientifica sulle malattie ematologiche. FRANCO MANDELLI

GITMO

Presentation



Leukemia is at the crossroads of hematology and oncology. It encompasses such a heterogeneous spectrum of disease entities that it is hard to preserve a unity. There is surely a greater difference between an indolent chronic lymphocytic leukemia and an acute leukemia, whether lymphoid or myeloid or mixed, than between acute lymphoblastic leukemia and most high grade non-Hodgkin's lymphomas. Yet, these malignancies composed of circulating cells, involving the bone marrow and encroaching on some of the most fundamental functions of the living organism, internal respiration, immunity and hemostasis, are of special interest to hematologists and oncologists. They also pose an enormous problem: the cure of leukemia. This is certainly one of the most exciting challenges for modern scientific medicine.


Fascinating modern technologies have opened entirely new avenues of investigation. Quite frequently, new findings in leukemic disorders have also elucidated important processes of normal physiology; this is particulary so in the lymphoproliferative diseases. However, there has been up to now a certain divergence between basic science in leukemia (derangement of the genome, growth factors, oncogenes, viruses) and therapy, which has been, and still is, mainly eradicative, with chemotherapy and bone marrow transplantation, allogeneic and autologous, in the foreground.

We seem to be approaching an era in which both trends will implement each other, allowing greater insight in to the basic processes and, at the same time, more integrated targeted and efficient therapies.
With this goal in mind, the program of this Conference is centered on a highly qualified international and Italian faculty to allow a broad and interactive exchange of experiences and opinions, as well as to share the most exciting advances between speakers and participants.

Addressed to

Physicians specialized in Hematology and Oncology

Program



Thursday, May 24

13.00 **Welcome and introduction**
A.M. Carella

MYELODYSPLASTIC SYNDROMES
Chairmen: E. Angelucci
P. De Fabritiis

13.15 **WHO classification**
P. Musto

13.30 **Somatic mutations in the novo MDS and prognosis**
W.K. Hofmann

13.45 **Therapy for lower risk patients**
R. Latagliata

14.00 **Therapy for higher risk patients**
V. Santini

14.15 **Novel agents**
P. Fenaux

14.45 **Timing of allografting**
M.G. Della Porta

15.00 **General discussion**

15.30 **Concluding remarks**
W.K. Hofmann

15.45 *Break*

16.15 **JOHN GOLDMAN LECTURE**
Presenter: A.M. Carella
Speaker: J.L. Steegmann

CHRONIC MYELOID LEUKEMIA
Chairmen: G. Saglio
G. Specchia

16.45 **First line therapy: still imatinib in all cases?**
J.F. Apperley

17.00 **Second line therapy: new options?**
F. Castagnetti

17.15 **ELN management recommendations**
A. Hochhaus

17.30 **Treatment discontinuation: time for clinical practice?**
F.X. Mahon

17.45 **TKIs: comorbidities and side effects**
M. Breccia


18.00 **Can we afford a continuous TKI therapy for a life-long period?**
E. Abruzzese

18.15 **Future biological and clinical perspectives**
M. Mauro

18.45 **General discussion**

19.00 **Concluding remarks**
G. Saglio

19.15 **End of the session**



Friday, May 25

PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
Chairmen: G. Cimino
A.M. Vannucchi

8.30 **Role of driver mutations in pathogenesis**
W. Vainchenker

8.45 **Clinical significance of mutations**
E. Rumi

9.00 **Does early treatment of MF make sense?**
F. Passamonti

9.15 **Novel treatment approaches beyond JAK2 inhibitors**
S. Giraudier

9.30 **Allografting in myelofibrosis**
W. Arcese

9.45 **General discussion**

10.15 **Concluding remarks**
A.M. Vannucchi

10.30 *Break*

NEW DRUGS AND NEW DATA WITH OLD DRUGS
Chairmen: G. Avvisati
R.M. Lemoli

11.00 **Update of Blinatumomab and Inotuzumab Ozogamicin in ALL**
F. Ferrara

11.15 **Target antigens and adoptive immunotherapy in AML**
A. Isidori

11.30 **FLT3 inhibitors**
S. Sica

11.45 **Venetoclax**
F. Pane

12.00 **BCR/BCL2 pathways inhibitors in CLL**
P.P. Ghia

12.15 **Obinutuzumab in lymphomas and CLL**
U. Vitolo

12.30 **Immune check-point inhibitors: from lymphomas to new perspectives**
G. Martinelli

12.45 **General discussion**

13.00 *Break*

ACUTE MYELOID LEUKEMIA
Chairmen: S. Amadori
A. Tafuri

14.00 **Mutations of clinical relevance**
B. Falini

14.15 **Beyond standard induction chemotherapy: new approaches for frontline therapy**
N. Russell



14.30 **MRD monitoring: clinical applications and pitfalls**
F. Buccisano

14.45 **New concepts in the management of older patients**
G.J. Ossenkoppele

15.00 **Allografting: who, when, how**
F. Ciceri

15.15 **New agents in clinical trials**
A. Ganser

15.30 **General discussion**

16.00 **Concluding remarks**
N. Russell

16.15 *Break*

ACUTE LYMPHOBLASTIC LEUKEMIA
Chairmen: R. Foà
M. Vignetti

16.30 **MRD-driven management of Ph-negative ALL**
A. Rambaldi

16.45 **Where are we going in the management of Ph-positive ALL?**
O.G. Ottmann

17.00 **New genetic-based strategies**
S. Chiaretti

17.15 **What will be the role of MoAb?**
P. Rousselot


17.30 **Ex vivo growth of primary ALL and drug response profiling**
J.P. Bourquin

17.45 **Allografting: when and how?**
A. Ibatici

18.00 **General discussion**

18.30 **Concluding remarks**
O.G. Ottmann

18.45 **End of the Conference**



Scientific Coordinator

Angelo Michele Carella
Past-Director
Division of Hematology and BMT Unit
San Martino University Hospital
Genoa
Hematology Consultant
Clinica Villa Pia, Rome
Centro Pacini, Milan

Scientific Board

Sergio Amadori
Institute of Hematology
Tor Vergata University Hospital
Rome

Emanuele Angelucci
Division of Hematology
and BMT Unit
San Martino University Hospital
Genoa

Robin Foà
Institute of Hematology
Sapienza University of Rome

Giuseppe Saglio
Division of Hematology
Mauriziano Hospital
University of Turin

Alessandro M. Vannucchi
CRIMM-Center of Research and
Innovation of Myeloproliferative
Neoplasms
Careggi University Hospital
University of Florence



Speakers and Discussant

Elisabetta Abruzzese
Rome

Jane F. Apperley
London (UK)

William Arcese
Rome

Giuseppe Avvisati
Rome

Jean-Pierre Bourquin
Zurich (CH)

Massimo Breccia
Rome

Francesco Buccisano
Rome

Fausto Castagnetti
Bologna

Sabina Chiaretti
Rome

Fabio Ciceri
Milan

Giuseppe Cimino
Latina

Paolo De Fabritiis
Rome

Matteo G. Della Porta
Rozzano, MI

Brunangelo Falini
Perugia

Piere Fenaux
Paris (F)

Felicetto Ferrara
Naples

Arnold Ganser
Hannover (D)


Paolo P. Ghia
Milan

Stephan Giraudier
Créteil (F)

Andreas Hochhaus
Jena (D)

Wolf-Karsten Hofmann
Mannheim (D)

Adalberto Ibatici
Genoa



Alessandro Isidori
Pesaro

Roberto Latagliata
Rome

Roberto M. Lemoli
Genoa

François-Xavier Mahon
Bordeaux (F)

Giovanni Martinelli
Bologna

Michael Mauro
New York (USA)

Pellegrino Musto
Rionero in Vulture, PZ

Oliver G. Ottmann
Cardiff (UK)

Gert J. Ossenkoppele
Amsterdam (NL)

Fabrizio Pane
Naples

Francesco Passamonti
Varese

Alessandro Rambaldi
Bergamo

Philippe Rousselot
Le Chesnay (F)

Elisa Rumi
Pavia

Nigel Russell
Nottingham (UK)

Valeria Santini
Florence

Simona Sica
Rome

Giorgina Specchia
Bari

Juan Luis Steegmann
Madrid (E)

Agostino Tafuri
Rome

William Vainchenker
Villejuif (F)

Marco Vignetti
Rome

Umberto Vitolo
Turin



CME

Based on Italian regulations, Accademia Nazionale di Medicina (provider n.31-217736) will assign **9.8 CME** credits to the activity.
The meeting is addressed to physicians specialized in Hematology and Oncology.
It will not be possible to give credits to physicians specialized in different fields.

The credit certification in subject to:
- attendance at 90% of the Meeting
- the completion of the meeting evaluation form
- the completion of the final questionnaire (at least 75% of correct answer).

We would like to remind to participants that only 1/3 of the CME Credits acquired during the years 2017-2019 can come from a sponsorship.

Official Language

The meeting will be held in Italian and English.
Simultaneous translation will be not provided.


Registration

The participation to the Meeting is free and is addressed to a limited number of participants.

To register, please send **by May 14, 2018**:
- registration form duly filled out
- privacy statement and consent regarding personal information (back of the form)

to Accademia Nazionale di Medicina - Via M. Piaggio 17/6 - 16122 Genova
fax. 010 83794260
e-mail: segreteriacorsi@accmed.org

It's also possible to register on the website https://leukemia.accmed.org
The registration will be confirmed by e-mail, please indicate your e-mail address on the registration form.



Venue

The Duke Hotel
Via Archimede, 69
Rome

How to reach the Venue

The Duke Hotel is located in the Villa Borghese area about 1.2 km from the Historical Centre of Rome, just 20 minutes walking from Piazzale Flaminio or 5 minutes with the Hotel complimentary shuttle bus.

by plane:
From the airport take the train to Termini Station, then underground A to Flaminio or the bus N. 910 to Piazza Euclide which is just 5 minutes walking to the Hotel.

by train:
- underground A to Flaminio or the bus N. 910 to Piazza Euclide which is just 5 minutes walking to the Hotel.
- from Piazzale Flaminio or Flaminio Underground station the Hotel is reachable in our complimentary shuttle bus service, in train Line Roma - Viterbo (only one stop) or bus N. 492.
- from piazza Euclide it is only 5 minutes walking to the hotel.

Promoted by

ACCADEMIA NAZIONALE DI MEDICINA

TÜV InterCert SAAR ISO 9001 SYSTEM CERTIFIED
07-Q-00019-TIC

www.accmed.org
General Manager: Stefania Ledda



Information and Registration

Tel 010 83794225
Fax 010 83794260
segreteriacorsi@accmed.org

https://leukemia.accmed.org

Organizing Partner

Forum Service
Via Martin Piaggio 17/6
16122 Genova



With the unconditioned sponsorship of

SILVER SPONSOR

AMGEN

BRONZE SPONSOR

abbvie

Bristol-Myers Squibb Otsuka

Celgene

Daiichi-Sankyo cancerenterprise

GILEAD

Incyte

MSD

NOVARTIS

Pfizer Oncology

sunesis Pharmaceuticals, Inc.